secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001493152-26-009471
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity licenses biomaterials portfolio for up to $35M; retains manufacturing, cuts costs
--------------------------------------------------------------------------------

- Up to $35M cash: $15M upfront plus $20M milestone payments based on net sales targets.
- Celularity will act as exclusive manufacturer of licensed products at its New Jersey FDA-compliant facility.
- Workforce reduction and organizational realignment expected to lower operating costs and sharpen focus on longevity therapeutics.
- Transaction expected to close no later than April 15, 2026, subject to customary conditions including financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000149315226009471/0001493152-26-009471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000149315226009471/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer